Ignite Creation Date:
2025-12-24 @ 11:40 PM
Ignite Modification Date:
2025-12-25 @ 9:30 PM
Study NCT ID:
NCT01834651
Status:
COMPLETED
Last Update Posted:
2017-09-27
First Post:
2013-04-01
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases
Sponsor:
Edwin Posadas, MD
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
XL184-IST20
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None